Xuefei Wang, MD, phD
Fudan University
3
3
0
N/A
0
2
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+2 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Yoon-Koo Kang, MD, PhD
Asan Medical Center
Shared therapeutic areas:
Heinz-Josef Lenz, MD
University of Southern California
Shared therapeutic areas:
Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shared therapeutic areas:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Shared therapeutic areas:
Jane Robertson, BSc, MBCHB, MD
AstraZeneca
Shared therapeutic areas:
Gregory Reid, MSc, MBA
MethylGene Inc.
Shared therapeutic areas:
Deborah E Citrin, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Robert L. DeJager, MD, FACP
Daiichi Sankyo
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy
All 3 trials loaded